Cargando…

Tofacitinib Treatment in Patients With Active COVID-19 Infection

Alopecia areata is a chronic autoimmune disorder attacking the hair follicle epithelium; hence, causing non-scarring hair loss. It has been found that Janus kinase 3 (JAK3) hyperactivity plays a key role in the pathogenesis of the disease. Tofacitinib is an effective JAK1 and JAK3 inhibitor that can...

Descripción completa

Detalles Bibliográficos
Autores principales: Alajlan, Abdulmajeed M, AlZamil, Lama R, Aseri, Amal M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516018/
https://www.ncbi.nlm.nih.gov/pubmed/34660145
http://dx.doi.org/10.7759/cureus.17957
_version_ 1784583722318692352
author Alajlan, Abdulmajeed M
AlZamil, Lama R
Aseri, Amal M
author_facet Alajlan, Abdulmajeed M
AlZamil, Lama R
Aseri, Amal M
author_sort Alajlan, Abdulmajeed M
collection PubMed
description Alopecia areata is a chronic autoimmune disorder attacking the hair follicle epithelium; hence, causing non-scarring hair loss. It has been found that Janus kinase 3 (JAK3) hyperactivity plays a key role in the pathogenesis of the disease. Tofacitinib is an effective JAK1 and JAK3 inhibitor that can block several cytokines such as IL-2, IL-7, and IL-6. Several studies have demonstrated the efficacy of oral tofacitinib in hair regrowth in alopecia areata patients. With the recent COVID-19 pandemic, it has been advised to withhold JAK inhibitors during the period of active infection due to possible immunosuppression. We herein report two cases of patients with alopecia universalis who continued to use tofacitinib during their active COVID-19 infection and showed no deterioration in their course of illness.
format Online
Article
Text
id pubmed-8516018
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-85160182021-10-15 Tofacitinib Treatment in Patients With Active COVID-19 Infection Alajlan, Abdulmajeed M AlZamil, Lama R Aseri, Amal M Cureus Dermatology Alopecia areata is a chronic autoimmune disorder attacking the hair follicle epithelium; hence, causing non-scarring hair loss. It has been found that Janus kinase 3 (JAK3) hyperactivity plays a key role in the pathogenesis of the disease. Tofacitinib is an effective JAK1 and JAK3 inhibitor that can block several cytokines such as IL-2, IL-7, and IL-6. Several studies have demonstrated the efficacy of oral tofacitinib in hair regrowth in alopecia areata patients. With the recent COVID-19 pandemic, it has been advised to withhold JAK inhibitors during the period of active infection due to possible immunosuppression. We herein report two cases of patients with alopecia universalis who continued to use tofacitinib during their active COVID-19 infection and showed no deterioration in their course of illness. Cureus 2021-09-14 /pmc/articles/PMC8516018/ /pubmed/34660145 http://dx.doi.org/10.7759/cureus.17957 Text en Copyright © 2021, Alajlan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Alajlan, Abdulmajeed M
AlZamil, Lama R
Aseri, Amal M
Tofacitinib Treatment in Patients With Active COVID-19 Infection
title Tofacitinib Treatment in Patients With Active COVID-19 Infection
title_full Tofacitinib Treatment in Patients With Active COVID-19 Infection
title_fullStr Tofacitinib Treatment in Patients With Active COVID-19 Infection
title_full_unstemmed Tofacitinib Treatment in Patients With Active COVID-19 Infection
title_short Tofacitinib Treatment in Patients With Active COVID-19 Infection
title_sort tofacitinib treatment in patients with active covid-19 infection
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516018/
https://www.ncbi.nlm.nih.gov/pubmed/34660145
http://dx.doi.org/10.7759/cureus.17957
work_keys_str_mv AT alajlanabdulmajeedm tofacitinibtreatmentinpatientswithactivecovid19infection
AT alzamillamar tofacitinibtreatmentinpatientswithactivecovid19infection
AT aseriamalm tofacitinibtreatmentinpatientswithactivecovid19infection